Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 214334, held by Hikma. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 214334 (Ephedrine Sulfate), held by Hikma, was first approved by FDA on Dec 15, 2020, with 0 approved supplements and 0 published complete response letters.
Ephedrine Sulfate Injection, USP is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 15, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters